we are party to license agreements with Duke University, under which we have exclusive rights to commercialize medical treatment products and procedures based on Duke’s thermo-sensitive liposome technology
Imunon, Inc. entered into a securities purchase agreement with Streeterville Capital, LLC, providing for the issuance and sale by the Company, and the purchase by the Investor, of Series A Preferred …
in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase II clinical develop…
Reciprocal relationship from HRZN graph: Reciprocal relationship from IMNN graph: in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized…
in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase II clinical develop…
in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase II clinical develop…
Imunon, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IMNN-DEBT
Debt stack $912,000
90%
Market cache reports total debt of $912,000.
IMNN-DEBT-10245
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
IMNN-DEBT-10244
Warrants outstanding: 4059
90%
xbrl warrant detail from xbrl 2025-12-31.
Imunon, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Imunon, Inc..
Imunon, Inc. Ownership
Holder
Name
Confidence
Evidence
IMNN-OWNER-OSAIC-HOLDINGS-INC
OSAIC HOLDINGS, INC.
90%
13F overlay lists OSAIC HOLDINGS, INC. as top holder; 3 tracked holders.
